CTRI/2024/04/066269尚未招募4 期
Assessment of Safety and Efficacy of Romiplostim in Live Donor Liver Transplant Recipients- A Prospective Randomized Open Label Trial - not applicable
Amrita School of Pharmacy0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Patient with the age group of 18-65years. Patients with a platelet count below 40000 Patient who signed the informed consent form
排除标准
- •Pregnancy, age under 18 or over 65,
- •ongoing multiple organ failure, antiplatelet therapy,
- •suspected/ diagnosed heparin-induced thrombocytopenia or innate/acquired thrombophilia. Patients with myelodysplastic or myeloproliferative syndrome, hematological malignancy, and aplasia diagnosed on bone marrow.
- •severe liver cirrhosis with a Child-Pugh score superior to 6, or a medical history of pulmonary embolism/stroke in the previous 6 months were also excluded.
研究者
相似试验
招募中
2 期
Romiplostim in treatment-naïve acquired aplastic anemiaIRCT20221129056655N2Shiraz University of Medical Sciences23
招募中
2 期
Romiplostim in treatment-refractory acquired aplastic anemiaIRCT20221129056655N1Shiraz University of Medical Sciences24
尚未招募
不适用
Study of efficacy of romiplostim for unreactive condition in platelet transfusion after cord blood transplantatiocord blood transplantationJPRN-UMIN000009276First Department of Internal Medicine, Kansai Medical University5
招募中
Unknown
Evaluation of the effecacy and safety of Risdiplam and Nusinersen in patients with Spinal Muscular Atrophy ??(SMA)Spinal muscular atrophy.Spinal muscular atrophy and related syndromesIRCT20131012014988N8Tabriz University of Medical Sciences40
尚未招募
不适用
Evaluation of the efficacy and safety of romosozumab alone and romosozumab + denosumab combination for patients with osteoporosis treated with 2-year denosumabosteoporosisJPRN-UMIN000037123Shinshu University School of Medicine Dept. of Orthopaedic Surgery60